問卷

TPIDB > Search Result

Search Result

篩選

List

17Cases

2025-04-01 - 2027-12-31

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential administration of THIO and Cemiplimab (LIBTAYO®) versus single-agent chemotherapy of the trial administrator's choice in advanced/metastatic non-small cell lung cancer (NSCLC).
  • Condition/Disease

    OS (defined as the time elapsed from random assignment to death for any reason)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2022-05-01 - 2026-03-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-06-01 - 2029-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-12-01 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-04-01 - 2028-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2025-03-04

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2025-10-01 - 2027-10-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-01-22 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2024-11-15 - 2027-02-16

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2